Using Salvia officinalis as an adjuvant therapy alongside routine vaginal Clotrimazole could favorably evade recurrent vulvovaginal candidiasis after three months, as deciphered from a recent randomized triple-blinded clinical trial. Researchers sought to investigate the effects of vaginal Salvia officinalis, Clotrimazole, and their combination for recurrent infection prevention in 111 females (age 18-49 years) suffering from vulvovaginal candidiasis.

The recruited volunteers were randomized to receive vaginal tablets of (1)  400 mg Salvia officinalis and placebo of 100 mg Clotrimazole, (2) 100 mg Clotrimazole and placebo of 400 mg Salvia officinalis, and (3) Salvia officinalis and Clotrimazole that were used every night for seven subsequent days.

Wet test results and determination of vaginitis symptoms performed after 12 weeks were used to determine the vulvovaginal candidiasis recurrence rate. If the evaluation was positive, vaginal discharge culture was carried out.  Overall, 35 patients (97.2%) in the Salvia officinalis-Clotrimazole group, 33 patients (94.3%) in the Salvia officinalis group, and 29 patients (80.6%) in the Clotrimazole group received treatment.

Out of cured people, four (13.8%) patients in the Clotrimazole group, one (3%) patient in the Salvia officinalis group, and no cases in the Salvia officinalis-Clotrimazole group  experienced infection recurrence. Regarding recurrence, there was a considerable difference among the study groups. Additionally, no unfavorable events were noticed in the 12 weeks following treatment.